Page last updated: 2024-12-09

diphenyleneiodium chloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dibenziodolium chloride : An organic chloride salt having dibenziodolium as the counterion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2733504
CHEMBL ID397686
CHEBI ID77967
SCHEMBL ID159318
MeSH IDM0355925

Synonyms (47)

Synonym
LS-14040
HMS3266G10
EU-0100367
diphenyleneiodonium chloride, >=98%
dpi
diphenyleneiodonium chloride
NCGC00093801-01
D 2926
[1,1'-biphenyl]-2,2'-diyiodonium chloride
CHEMBL397686 ,
dibenziodolium chloride
chebi:77967 ,
4673-26-1
NCGC00093801-02
HMS3261I15
unii-7m9d81yz2n
7m9d81yz2n ,
LP00367
AKOS015903219
CCG-221671
gtpl7802
SCHEMBL159318
2,2'-biphenylyleneiodonium chloride
dibenzo[b,d]iodolium chloride
tox21_500367
NCGC00261052-01
[1,1'-biphenyl]-2,2'-diyliodonium chloride
mfcd00214165
DTXSID00196932
SR-01000075494-3
sr-01000075494
SR-01000075494-1
dibenzo[b,d]iodol-5-ium chloride
CS-0020645
HY-100965
Q4162480
diphenyleneiodonium chloride - cas 4673-26-1
dibenziodolium, chloride
HMS3675A10
BCP08692
HMS3411A10
A13359
8-iodoniatricyclo[7.4.0.0^{2,7]trideca-1(13),2,4,6,9,11-hexaene;chloride
HMS3867D13
HMS3886J12
dpi chloride
8-iodoniatricyclo[7.4.0.02,7]trideca-1(13),2,4,6,9,11-hexaene;chloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitorAn EC 1.6.3.* (oxidoreductase acting on NADH or NADPH with oxygen as acceptor) inhibitor that interferes with the action of NAD(P)H oxidase (H2O2-forming), EC 1.6.3.1.
G-protein-coupled receptor agonistAn agonist that binds to and activates G-protein-coupled receptors
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
organic chloride salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency29.10560.003245.467312,589.2998AID1705; AID2517; AID2572
endonuclease IVEscherichia coliPotency44.66840.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency22.98330.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency0.10270.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency4.46680.00527.809829.0929AID588855
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency6.30960.28189.721235.4813AID2326
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency0.02600.001530.607315,848.9004AID1224819; AID1224820; AID1224821
67.9K proteinVaccinia virusPotency11.29470.00018.4406100.0000AID720579; AID720580
Bloom syndrome protein isoform 1Homo sapiens (human)Potency15.84890.540617.639296.1227AID2364
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency0.213323.934123.934123.9341AID1967
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.20600.00419.984825.9290AID720524
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
DNA polymerase betaHomo sapiens (human)Potency28.18380.022421.010289.1251AID485314
flap endonuclease 1Homo sapiens (human)Potency50.11870.133725.412989.1251AID588795
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency32.12200.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency3.48040.004611.374133.4983AID463097; AID504364
survival motor neuron protein isoform dHomo sapiens (human)Potency0.11220.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency6.35150.891312.067628.1838AID1459; AID1487
Glutamate receptor 1Rattus norvegicus (Norway rat)Potency39.81070.01418.602439.8107AID2572
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency39.81070.001551.739315,848.9004AID2572
Glutamate receptor 3Rattus norvegicus (Norway rat)Potency39.81070.01418.602439.8107AID2572
Glutamate receptor 4Rattus norvegicus (Norway rat)Potency39.81070.01418.602439.8107AID2572
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydroorotate dehydrogenase Plasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)10.00000.23002.64439.4800AID370979
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1160718Inhibition of bovine milk xanthine oxidase assessed as hypoxanthine-stimulated ROS generation by measuring H2O2 production at 25 to 50 uM by fluorescence assay2013MedChemComm, Jul, Volume: 4, Issue:7
Bridged tetrahydroisoquinolines as selective NADPH oxidase 2 (Nox2) inhibitors.
AID370981Antimalarial activity against Plasmodium falciparum DD2 by [3H]hypoxanthine uptake2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID418480Inhibition of fMLP/cytochalasin B-stimulated super oxide anion generation in Sprague-Dawley rat neutrophils2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis, anti-inflammatory, and antioxidant activities of 18beta-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors.
AID370982Antimalarial activity against Plasmodium falciparum DD2 expressing Saccharomyces cerevisiae DHOD by [3H]hypoxanthine uptake2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID370978Inhibition of Plasmodium falciparum NDH22009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID294585Inhibition of 0.3 uM fMLP-stimulated superoxide anion generation in rat neutrophils2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Synthetic 2',5'-dimethoxychalcones as G(2)/M arrest-mediated apoptosis-inducing agents and inhibitors of nitric oxide production in rat macrophages.
AID370980Inhibition of Saccharomyces cerevisiae DHOD2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID294586Inhibition of 3 nM PMA-stimulated superoxide anion generation in rat neutrophils2007European journal of medicinal chemistry, May, Volume: 42, Issue:5
Synthetic 2',5'-dimethoxychalcones as G(2)/M arrest-mediated apoptosis-inducing agents and inhibitors of nitric oxide production in rat macrophages.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID454663Inhibition of fMLP-induced superoxide generation in Sprague-Dawley rat neutrophils2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Furo[3',2':3,4]naphtho[1,2-d]imidazole derivatives as potential inhibitors of inflammatory factors in sepsis.
AID418481Inhibition of PMA-stimulated super oxide anion generation in Sprague-Dawley rat neutrophils2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis, anti-inflammatory, and antioxidant activities of 18beta-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors.
AID1478715Inhibition of LPS-stimulated ROS production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation after 24 hrs by CMH2DCFDA probe-based fluorescence assay2017European journal of medicinal chemistry, Jun-16, Volume: 133Design, synthesis, and structure-activity relationship study of halogen containing 2-benzylidene-1-indanone derivatives for inhibition of LPS-stimulated ROS production in RAW 264.7 macrophages.
AID370979Inhibition of Plasmodium falciparum DHOD2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Type II NADH dehydrogenase of the respiratory chain of Plasmodium falciparum and its inhibitors.
AID454664Inhibition of PMA-induced superoxide generation in Sprague-Dawley rat neutrophils2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Furo[3',2':3,4]naphtho[1,2-d]imidazole derivatives as potential inhibitors of inflammatory factors in sepsis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1346870Human GPR3 (Class A Orphans)2014The Journal of pharmacology and experimental therapeutics, Jun, Volume: 349, Issue:3
Identification of a novel small-molecule agonist for human G protein-coupled receptor 3.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (54.55)29.6817
2010's4 (36.36)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.93 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]